# Humigent

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/humigent

- Industry: Software
- Headquarters: Iselin, US
- Website: www.humigent.ai/
- Latest round: Series A (Jul 29, 2026)
- Investors on record: 2

## About

Based in the US, Humigent provides innovative applied AI solutions tailored for the life sciences sector, specifically servicing pharmaceutical and biotechnology organizations.Humigent, founded in 2025, operates in Iselin, US. The company specializes in AI solutions for the life sciences sector. It has completed a single deal as of July 29, 2026, highlighting its focus on establishing a foothold in its market.Humigent specializes in providing applied AI solutions tailored for the life sciences sector, specifically targeting pharmaceutical and biotechnology organizations. Their core offerings include the HumigentLM model, a 30 billion-parameter AI system designed for commercial, medical, and access data, which boasts a Life Sciences-specific vocabulary and context. Additional solutions encompass an expandable library of agents that facilitate ingestion, validation, summarization, and auditing tasks, all coordinated by a central Decision Engine. These products are designed to enhance workflow efficiency and accuracy, reducing the occurrence of hallucinations through a specialized semantic layer and advanced cognitive architecture. Humigent's clientele includes pharmaceutical and biotech teams operating in various geographical markets, including North America, Europe, and Asia, where they apply these solutions to streamline operations and drive growth.Humigent generates revenue through direct partnerships and subscriptions, focusing on B2B transactions with its clients in the pharmaceutical and biotechnology sectors. The firm's financial model is centered around offering integrated AI solutions, which are packaged into multi-year subscription agreements to provide sustained access to its software and analytics capabilities. The structure may include tiered pricing plans based on the scale and complexity of the services, allowing clients to select options that best fit their needs. This transactional framework enables Humigent to establish long-term relationships with its customers, fostering collaboration in deploying AI technologies that enhance operational efficiency and decision-making within their organizations.In July 2026, Humigent raised an undisclosed amount in Series A funding from new investors Z21 Ventures and First Rays Venture Partners. The company will use the funding to enhance its artificial intelligence platform, expand its life sciences solutions, and support wider adoption across pharmaceutical and biotechnology organizations. Upcoming product launches and expansions into new geographic regions are part of Humigent's strategy for growth.

## Funding rounds

- Series A, Jul 29, 2026 — First Rays Venture Partners, Z21 Ventures

## Investors

- First Rays Venture Partners (https://capitalatlas.ai/funds/first-rays-venture-partners) — Series A
- Z21 Ventures (https://capitalatlas.ai/funds/z21-ventures) — Series A